PureSu is ideal for the end-to-end manufacture of biopharmaceuticals and personalized medicines, such as gene therapies. The expanded range consists of three new product options: sterile claim, gamma irradiated, and non-irradiated. WMFTG’s PureSu assemblies offer a unique solution to the challenges of bioprocessing, providing controlled, efficient, and reliable single-use assemblies that simplifies validation processes. Offering open architecture design by using the single-use components customer can quickly create a sterile, fluid path that meets their specific bioprocessing needs. For more information, visit www.wmftg.com.